pd 169316 has been researched along with Bone Loss, Osteoclastic in 1 studies
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karsdal, MA | 1 |
| Fjording, MS | 1 |
| Foged, NT | 1 |
| Delaissé, JM | 1 |
| Lochter, A | 1 |
1 other study available for pd 169316 and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Transforming growth factor-beta-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway.
Topics: 3T3 Cells; Animals; Blotting, Western; Bone Resorption; Cell Division; Cell-Free System; Cells, Cult | 2001 |